CA2439265A1 - Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function - Google Patents

Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function Download PDF

Info

Publication number
CA2439265A1
CA2439265A1 CA002439265A CA2439265A CA2439265A1 CA 2439265 A1 CA2439265 A1 CA 2439265A1 CA 002439265 A CA002439265 A CA 002439265A CA 2439265 A CA2439265 A CA 2439265A CA 2439265 A1 CA2439265 A1 CA 2439265A1
Authority
CA
Canada
Prior art keywords
alpha
isoindole
dione
tetrahydro
hexahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002439265A
Other languages
English (en)
French (fr)
Inventor
Dacia A. Pickering
Ricardo M. Attar
Mark E. Salvati
James A. Balog
Rogelio L. Martinez
Chongqing Sun
Marco M. Gottardis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2439265A1 publication Critical patent/CA2439265A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
CA002439265A 2001-02-27 2002-02-20 Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function Abandoned CA2439265A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27167201P 2001-02-27 2001-02-27
US60/271,672 2001-02-27
PCT/US2002/005302 WO2002067939A1 (en) 2001-02-27 2002-02-20 Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

Publications (1)

Publication Number Publication Date
CA2439265A1 true CA2439265A1 (en) 2002-09-06

Family

ID=23036570

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002439265A Abandoned CA2439265A1 (en) 2001-02-27 2002-02-20 Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

Country Status (6)

Country Link
US (2) US20040087548A1 (US07655688-20100202-C00473.png)
EP (1) EP1379249A4 (US07655688-20100202-C00473.png)
JP (1) JP2004523558A (US07655688-20100202-C00473.png)
CA (1) CA2439265A1 (US07655688-20100202-C00473.png)
HU (1) HUP0304055A2 (US07655688-20100202-C00473.png)
WO (1) WO2002067939A1 (US07655688-20100202-C00473.png)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7001911B2 (en) * 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
EP1854798A3 (en) * 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
SI1454903T1 (sl) * 2001-12-11 2010-12-31 Kyowa Hakko Kirin Co Ltd Tiadiazolinski derivati za zdravljenje raka
JP4434740B2 (ja) * 2001-12-19 2010-03-17 ブリストル−マイヤーズ スクイブ カンパニー 核ホルモン受容体機能の調節剤である、縮合ヘテロ環化合物およびその類似体
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
JP4676881B2 (ja) * 2003-04-18 2011-04-27 協和発酵キリン株式会社 Ｍ期キネシン阻害剤
US20070276017A1 (en) * 2003-06-10 2007-11-29 Chikara Murakata Thiadiazoline Derivative
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
AU2004249250C1 (en) * 2003-06-20 2012-04-12 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US7737168B2 (en) 2003-06-20 2010-06-15 Siga Technologies, Inc. Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
JPWO2005035512A1 (ja) * 2003-10-10 2006-12-21 協和醗酵工業株式会社 チアジアゾリン誘導体
US8383637B2 (en) * 2004-08-06 2013-02-26 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8436006B2 (en) * 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8426429B2 (en) * 2004-08-06 2013-04-23 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
EP1836202B1 (en) * 2005-01-10 2016-12-21 Acadia Pharmaceuticals Inc. Aminophenyl derivatives as selective androgen receptor modulators
US20080262049A1 (en) * 2005-03-22 2008-10-23 Kyowa Hakko Kogyo Co., Ltd. Therapeutic Agent for Hematopoietic Tumor
AU2006225636A1 (en) * 2005-03-22 2006-09-28 Fujifilm Corporation Therapeutic agent for solid tumor
WO2006137490A1 (ja) * 2005-06-24 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. 再狭窄治療剤
WO2007092854A2 (en) * 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
WO2007092839A2 (en) * 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. Macrocycle derivatives useful as inhibitors of beta-secretase (bace)
US7776882B2 (en) * 2006-02-06 2010-08-17 Baxter Ellen W 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE)
US7468439B2 (en) * 2006-09-06 2008-12-23 Bristol-Myers Squibb Company Alkylene bridged sultam compounds useful as modulators of nuclear hormone receptor function
MX348481B (es) 2007-04-23 2017-06-15 Siga Tech Inc Productos quimicos, composiciones y metodos para tratamiento y prevencion de infecciones de virus orthopox y enfermedades asociadas.
US8466171B2 (en) * 2007-11-01 2013-06-18 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as modulators of nuclear hormone receptor function
NZ586831A (en) * 2008-01-28 2012-02-24 Janssen Pharmaceutica Nv 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace)
NZ586830A (en) * 2008-01-29 2012-02-24 Janssen Pharmaceutica Nv 2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace)
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
WO2009155001A2 (en) 2008-05-27 2009-12-23 The Board Of Regents Of The University Of Texas System Wnt protein signalling inhibitors
JPWO2011007819A1 (ja) 2009-07-17 2012-12-27 塩野義製薬株式会社 ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬
US9339466B2 (en) 2010-03-23 2016-05-17 Siga Technologies, Inc. Polymorphic forms of ST-246 and methods of preparation
EP2735567B1 (en) * 2011-07-21 2016-10-26 Xuanzhu Pharma Co., Ltd. Heterocyclic substituted pyrimidine compound
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PL2782584T3 (pl) 2011-11-23 2021-12-13 Therapeuticsmd, Inc. Naturalne skojarzone hormonalne formulacje i terapie zastępcze
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN103193696B (zh) * 2013-04-18 2015-11-11 北京大学 降冰片烯基酰亚胺体系甲壳型聚合物单体及其聚合物
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
GB201507937D0 (en) * 2015-05-08 2015-06-24 Univ Hertfordshire Higher Education Corp Compounds for treatment of pancreatic cancer
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017095237A1 (en) * 2015-11-30 2017-06-08 Sammut Ivan Andrew Carbon monoxide releasing norbornenone compounds
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
EP3448381A1 (en) 2016-04-27 2019-03-06 Forschungsverbund Berlin E.V. Antagonists of the thyroid-stimulating hormone receptor (tshr)
CN106349160B (zh) * 2016-08-05 2019-07-26 浙江工业大学 一种8-氨基喹啉衍生物及其制备与应用
CN107954992A (zh) * 2017-12-15 2018-04-24 田元强 吡咯二酮衍生物及其在小菜蛾和桃蚜防治中的应用
CN110183456A (zh) * 2019-07-11 2019-08-30 河南师范大学 一种2-芳基吲唑琥珀酰亚胺螺环化合物的合成方法
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN113620969A (zh) * 2020-05-07 2021-11-09 贵州医科大学 带桥环的环己烷二羧酸衍生物及其药物组合物和应用
WO2023192782A2 (en) * 2022-03-27 2023-10-05 Board Of Regents, The University Of Texas System Small molecule inhibitors of lanosterol synthase

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320270A (en) 1963-10-08 1967-05-16 Tri Kem Corp Certain 2-acylimidothiazole compounds
US3215597A (en) 1963-10-30 1965-11-02 Dow Chemical Co Methods and compositions for use in animal husbandry
US3343940A (en) 1964-06-12 1967-09-26 Pennsalt Chemicals Corp Process for plant desiccation
US3261845A (en) 1964-07-14 1966-07-19 Dow Chemical Co N-phenyl derivatives of 3,6-epoxyhexahydrophthalimide
GB1039020A (en) 1964-09-21 1966-08-17 Biorex Laboratories Ltd Process for the preparation of 5-nitrofurfuraldehyde diacetate
US3428538A (en) 1966-01-13 1969-02-18 Peter Scheiner Method for preparing aziridines by photolysis of triazolines
JPS4916937B1 (US07655688-20100202-C00473.png) 1970-01-21 1974-04-25
US3821232A (en) 1971-12-20 1974-06-28 Petrolite Corp 1,2-dihydro-pyridine-n-phosphonates and thiophosphonates
US3965264A (en) 1971-12-20 1976-06-22 Petrolite Corporation Process for controlling microbiological organisms in aqueous or petroleum hydrocarbon systems
US3923490A (en) 1971-12-20 1975-12-02 Petrolite Corp Use of 1,2-dihydro-pyridine-N-phosphonates and thiophosphonates as microbiocides
US4089650A (en) 1971-12-20 1978-05-16 Petrolite Corporation Use of Diels-Alder adducts of dihydro-nitrogen heterocyclic phosphoramidates as corrosion inhibitors
US3998833A (en) 1971-12-20 1976-12-21 Petrolite Corporation Diels-alder adducts of dihydro-nitrogen heterocyclic phosphoramidates
JPS5032306B2 (US07655688-20100202-C00473.png) 1972-11-02 1975-10-20
US3925554A (en) 1972-11-30 1975-12-09 Sumitomo Chemical Co Certain 3,5-dichlorophenyl compound used as a plant fungicide
NL7501563A (nl) 1974-02-28 1975-09-01 Merck & Co Inc Werkwijze voor het bereiden van preparaten te- gen het samenpakken van bloedplaatjes.
US3997293A (en) 1974-03-19 1976-12-14 Petrolite Corporation Use of dihydro-nitrogen heterocyclic phosphoramidates as corrosion inhibitors
FR2329276A1 (fr) 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
EP0002309B1 (en) 1977-10-12 1982-12-01 Imperial Chemical Industries Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
CA1138334A (en) 1977-10-28 1982-12-28 Karl Bernauer Pharmaceutical preparations containing certain urea derivatives
MC1220A1 (fr) 1977-10-28 1979-07-20 Hoffmann La Roche Nouveaux derives d'imidazolidine
US4191775A (en) 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
FR2465486A1 (fr) 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
FR2492381A1 (fr) 1980-10-21 1982-04-23 Science Union & Cie Nouveaux acides aza bicyclo alcane carboxyliques substitues leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
DE3121152A1 (de) 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"
US4753957A (en) 1981-09-28 1988-06-28 Rohm And Haas Company Substituted 2,4-imidazolidinediones and fungicidal compositions
US5512676A (en) 1987-09-03 1996-04-30 The Boeing Company Extended amideimide hub for multidimensional oligomers
US5286811A (en) 1983-09-27 1994-02-15 The Boeing Company Blended polyimide oligomers and method of curing polyimides
US5367083A (en) 1987-09-03 1994-11-22 The Boeing Company Extended acid halide capping monomers
US5104967A (en) 1987-09-03 1992-04-14 The Boeing Company Amideimide oligomers and blends
US5780583A (en) 1991-01-09 1998-07-14 The Boeing Company Reactive polyarylene sulfide oligomers
US5446120A (en) 1985-10-07 1995-08-29 The Boeing Company Polyethersulfone oligomers and blends
US5693741A (en) 1988-03-15 1997-12-02 The Boeing Company Liquid molding compounds
US4851495A (en) 1987-02-20 1989-07-25 The Boeing Company Polyetherimide oligomer
US5516876A (en) 1983-09-27 1996-05-14 The Boeing Company Polyimide oligomers and blends
US4536559A (en) 1983-06-17 1985-08-20 The Boeing Company Thermally stable polyimide polysulfone compositions for composite structures
US5155206A (en) 1987-09-03 1992-10-13 The Boeing Company Crosslinkable polyamideimide oligomers and a method of preparation
US5645925A (en) 1988-03-14 1997-07-08 Boeing Company Advanced composite blends
US4584364A (en) 1984-02-06 1986-04-22 The Boeing Company Phenolic-capped imide sulfone resins
US5210213A (en) 1983-06-17 1993-05-11 The Boeing Company Dimensional, crosslinkable oligomers
US5116935A (en) 1987-05-04 1992-05-26 The Boeing Company Polyimide oligomers and blends and method of curing
US4507303A (en) 1981-12-22 1985-03-26 Sumitomo Chemical Company, Limited Succinimide derivatives, compositions and method of use
DE3382406D1 (de) 1982-04-08 1991-10-17 Shell Int Research Neue hydantoine, ihre herstellung und verwendung.
DE3227055A1 (de) 1982-07-20 1984-01-26 Hoechst Ag, 6230 Frankfurt Neue derivate der 2-aza-bicyclo(2.2.2)octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie 2-aza-bicyclo(2.2.2)octan-3-carbonsaeure als zwischenstufe und verfahren zu deren herstellung
US4473393A (en) 1982-08-06 1984-09-25 Buffalo Color Corporation Pesticidal thiohydantoin compositions
JPS59118750A (ja) 1982-12-27 1984-07-09 Eisai Co Ltd カルボン酸アミド化合物およびその誘導体
US5112939A (en) 1983-06-17 1992-05-12 The Boeing Company Oligomers having pyrimidinyl end caps
US4980481A (en) 1983-06-17 1990-12-25 The Boeing Company End-cap monomers and oligomers
US4476184A (en) 1983-08-09 1984-10-09 The Boeing Company Thermally stable polysulfone compositions for composite structures
US4582886A (en) 1984-02-27 1986-04-15 General Electric Company Heat curable epoxy resin compositions and epoxy resin curing agents
US4562255A (en) 1984-03-30 1985-12-31 American Home Products Corporation Substituted bi-alicyclic imides
US4533737A (en) 1984-04-02 1985-08-06 General Electric Company Silicon functionalized norbornane carboxyimide and methods for making
GB8411928D0 (en) 1984-05-10 1984-06-13 Robinson Bros Ltd Preparing substituted oxazolines
US4760053A (en) 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4775660A (en) 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4666885A (en) 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US4659695A (en) 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
US4670536A (en) 1985-06-01 1987-06-02 Director-General Of Agency Of Industrial Science And Technology Addition-curable quinoxaline resin oligomer and intermediate material for fiber-reinforced composite
US5594089A (en) 1985-09-05 1997-01-14 The Boeing Company Heterocycle or heterocycle sulfone oligomers with multiple chemically functional end caps
US5610317A (en) 1985-09-05 1997-03-11 The Boeing Company Multiple chemically functional end cap monomers
US4656235A (en) 1985-09-05 1987-04-07 Polytechnic Institute Of New York Siloxane-containing polyimide coatings for electronic devices
US5151487A (en) 1985-09-30 1992-09-29 The Boeing Company Method of preparing a crosslinking oligomer
US4892943A (en) 1985-10-16 1990-01-09 American Home Products Corporation Fused bicyclic imides with psychotropic activity
GB8617653D0 (en) 1986-07-18 1986-08-28 Ici Plc Amide derivatives
US5084472A (en) 1986-11-04 1992-01-28 Roussel Application of 1-(3'-trifluoromethyl-4'-nitrophenyl)-4,4'-dimethylimidazoline 2,5-dione in the treatment of hormone-dependent cancers other than that of the prostate
FR2619381B1 (fr) 1987-08-13 1989-12-08 Roussel Uclaf Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
US4892578A (en) 1987-11-06 1990-01-09 Fmc Corporation Phenylmethyl-4,4-dimethyl-3-isoxazolidinone plant regulators
US5817744A (en) 1988-03-14 1998-10-06 The Boeing Company Phenylethynyl capped imides
US5595985A (en) 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
WO1990010462A1 (en) 1989-03-10 1990-09-20 Endorecherche Inc. Combination therapy for treatment of estrogen sensitive diseases
FR2649110B1 (fr) 1989-06-29 1994-10-21 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DK0943328T3 (da) 1989-07-07 2004-10-18 Endorech Inc Kombinationsterapi til profylakse og/eller behandling af godartet prostatahyperplasi
FR2656302B1 (fr) 1989-12-22 1992-05-07 Roussel Uclaf Nouveau procede de preparation de l'anandron et derives de l'anandron.
US5114612A (en) 1990-04-04 1992-05-19 The United States Of America As Represented By The Department Of Energy Liquid crystal polyester thermosets
JP2800953B2 (ja) * 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5093500A (en) 1990-10-17 1992-03-03 Shell Oil Company Spirodilactam bisimides
HUT62296A (en) 1990-12-18 1993-04-28 Sandoz Ag Herbicidal composition comprising hydantoin derivative as active ingredient and process for producing the active ingredient
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
IL107719A0 (en) 1992-12-21 1994-02-27 Du Pont Imidazolones their manufacture and their use as herbicides
DK0611885T3 (US07655688-20100202-C00473.png) 1993-02-17 1997-06-30 New Sulzer Diesel Ag
US5399725A (en) 1993-05-27 1995-03-21 Bristol-Myers Squibb Co. 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds and method for preparing same
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2716110B1 (fr) 1994-02-16 1996-04-05 Roussel Uclaf Compositions cosmétiques ou pharmaceutiques comprenant des liposomes.
US5539126A (en) 1994-04-20 1996-07-23 Bristol-Myers Squibb Company Method for preparing homochiral maleimide intermediates, via silylation techniques
GB9411800D0 (en) 1994-06-13 1994-08-03 Sandoz Ltd Organic compounds
EP0777458B1 (en) 1994-09-14 2000-12-06 Central Sheffield University Hospitals NHS Trust Control of hair growth
FR2742749B1 (fr) 1995-12-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines comportant notamment un radical nitrooxy ou carbonyloxy, procede et intermediaires de preparation, application comme medicaments, nouvelles utilisations et compositions pharmaceutiques
US6673927B2 (en) 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
US6017924A (en) * 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
EP0947513B1 (en) 1996-10-25 2004-05-19 Daiichi Pharmaceutical Co., Ltd. Tricyclic amine derivatives
US6071957A (en) 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US5929146A (en) 1996-12-27 1999-07-27 Minnesota Mining And Manufacturing Company Modifying agents for polyolefins
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
FR2764890B1 (fr) 1997-06-24 1999-08-27 Adir Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN1268137A (zh) 1997-07-03 2000-09-27 杜邦药品公司 治疗神经失调的咪唑并嘧啶和咪唑并吡啶
EP1024820A1 (en) 1997-08-28 2000-08-09 Janus Pharmaceuticals, Inc. Androgen activity antagonists as therapies for anorexia, anorexia nervosa, and disorders characterized by a pathologically underweight condition
JP3887769B2 (ja) * 1997-12-22 2007-02-28 バイエル コーポレイション 対称および非対称ジフェニル尿素を用いるｐ３８キナーゼの阻害
BR9913503A (pt) 1998-09-09 2002-01-29 Ishihara Sangyo Kaisha Derivados de benzeno-fundidos úteis como herbicidas
US6297380B1 (en) 1998-11-23 2001-10-02 Pfizer Inc. Process and intermediates for growth hormone secretagogues
DE69909947T2 (de) 1998-12-02 2004-02-12 Nippon Paper Industries Co. Ltd. Tintenstrahlaufzeichnungsblatt mit einer Bildschutzschicht
JP2000169474A (ja) 1998-12-07 2000-06-20 Kotobuki Seiyaku Kk イソキヌクリジン誘導体及びその製造方法並びにこれを含有する高コレステロール血症治療剤
CA2356162A1 (en) 1998-12-22 2000-06-29 Eli Lilly And Company Substituted tricyclics
EP1140941B1 (en) 1998-12-23 2004-10-20 Bristol-Myers Squibb Pharma Company Nitrogen containing heterobicycles as factor xa inhibitors
GB9918962D0 (en) 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxii
GB9921150D0 (en) 1999-09-07 1999-11-10 Merck Sharp & Dohme Therapeutic agents
CZ20021210A3 (cs) 1999-10-08 2002-08-14 Grünenthal GmbH Bicyklické deriváty imidazo-3-yl-aminu, způsob jejich výroby, jejich pouľití a léčiva tyto látky obsahující
US6200573B1 (en) 1999-12-03 2001-03-13 Starcor Pharmaceuticals, Inc. Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
MXPA02012605A (es) * 2000-06-28 2003-05-14 Squibb Bristol Myers Co Moduladores selectivos del receptor androgeno y metodo para su identificacion, dise°o y uso.
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
EP1319007B9 (en) 2000-09-19 2007-10-10 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6710048B2 (en) 2000-09-20 2004-03-23 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
FR2818277B1 (fr) 2000-12-14 2003-01-24 Servier Lab Nouveaux derives bicycliques d'amino-pyrazinones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
OA12552A (en) 2001-03-09 2006-06-06 Pfizer Prod Inc Triazolopyridines as anti-inflammatory agents.
US6750225B2 (en) 2001-04-18 2004-06-15 Bristol-Myers Squibb Pharms Company 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors
EP1414795A4 (en) 2001-07-31 2006-03-01 Bristol Myers Squibb Co BICYCLIC MODULATORS OF THE FUNCTION OF THE ANDROGEN RECEPTOR
JP4434740B2 (ja) * 2001-12-19 2010-03-17 ブリストル−マイヤーズ スクイブ カンパニー 核ホルモン受容体機能の調節剤である、縮合ヘテロ環化合物およびその類似体
US7405234B2 (en) * 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
TW200407324A (en) * 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
JP4916662B2 (ja) 2002-06-19 2012-04-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ホスホジエステラーゼ阻害剤として有用な置換２，４−ジヒドロ−ピロロ（３，４−ｂ）−キノリン−９−オン誘導体

Also Published As

Publication number Publication date
US7655688B2 (en) 2010-02-02
US20040087548A1 (en) 2004-05-06
JP2004523558A (ja) 2004-08-05
EP1379249A4 (en) 2008-01-09
US20060111424A1 (en) 2006-05-25
WO2002067939A1 (en) 2002-09-06
EP1379249A1 (en) 2004-01-14
HUP0304055A2 (hu) 2004-04-28

Similar Documents

Publication Publication Date Title
US7655688B2 (en) Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7342034B2 (en) Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2001269943B2 (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7235563B2 (en) Spirocyclic compounds useful as modulators of nuclear hormone receptor function
EP1458723B1 (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7550458B2 (en) Tricycloundecane compounds useful as modulators of nuclear hormone receptor function
US20080214643A1 (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2002250163A1 (en) Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
ZA200210313B (en) Fused cyclic compounds as modulators of nuclear hormone receptor function.
RU2298554C2 (ru) Конденсированные гетероциклические сукцинимидные соединения

Legal Events

Date Code Title Description
FZDE Discontinued